Eicosanoid production and lymphatic responsiveness in human cigarette smokers compared with non-smokers

Lymphology

Volumn 33, Issue 1, 2000, Pages 24-31

  Sinzinger, Helmut ^a  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; CREATININE; ICOSANOID; PROSTACYCLIN;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHATIC SYSTEM; LYMPHOGRAPHY; MALE; PRIORITY JOURNAL; SYNTHESIS; THIN LAYER CHROMATOGRAPHY;

EICOSANOIDS; HUMANS; LYMPH; LYMPHATIC SYSTEM; OXIDATIVE STRESS; PROSTAGLANDINS; REFERENCE VALUES; SMOKING;

EID: 0034117621     PISSN: 00247766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Granger, DN, RE Parker, EW Anillu, et al: Lymph flow transients. Acta Physiol. Scand. 100 (1978), 61.
2. Schmid, P, G Karanikas, H Kritz, et al: Passive smoking and platelet thromboxane. Thromb. Res. 81(1996), 451-461.
3. Oguogho, A, P Schmid, H Kritz, et al: Quitting cigarette smoking results in a fast improvement of invivo oxidation injury (determined via plasma and urinary isoprostane). Wr. klin. Wschr. (1999), in press.
4. Sinzinger, H, A Kefalides: Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins. Lancet ii (1982), 392-393.
5. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. New Engl. J. Med. 332 (1995), 1198-1203.
6. 2) biosynthesis in arteries. Artery 7 (1980), 488-495.
7. 2α excretion in man. J. Pharmacol. Exp. Ther. 275 (1995), 94-100.
8. Morrow, ID, TA Minton, CR Mukundan, et al: Free radical-induced generation of isoprostanes invivo. Evidence for the formation of D-ring and E-ring isoprostanes in-vivo. J. Biol. Chem. 269 (1993), 4317-4326.
9. Sinzinger, H, J Kaliman, E Mannheimer: Regulation of human lymph contractility by prostaglandins and thromboxane. Lymphology 17 (1984), 43-45.
10. 2α is a potent contractor of human peripheral lymphatics. Lymphology 30 (1997), 155-159.
11. Johnston, MG, A Kanalec, JL Gordon: Products of arachidonic acid and its cyclooxygenase and lipoxygenase products on lymphatic vessel contractility in vitro. Prostaglandins 25 (1983), 85.
12. 2α) in human and porcine lymphatics and lymph. Lymphology 31 (1999), 186-189.
13. 2α in heterozygous hypercholesterolemia. Wr. klin. Wschr. 111 (1999), 113-118.
14. Johnston, MG, JL Gordon: Regulation of lymphatic contractility by arachidonic acid metabolites. Nature 293 (1981), 294.
15. Sinzinger, H, J Kaliman, E Mannheimer: Arachidonic acid metabolites of human lymphatics. Lymphology 17 (1984), 39-42.
16. Bunting, S, RJ Gryglewski, S Moncada, et al: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12 (1976), 897-913.
17. Mannheimer, E, H Sinzinger, R Oppolzer, et al: Prostacyclin synthesis in human lymphatics. Lymphology 13 (1980), 44-46.
18. Mizuno, R, A Koller, G Kaley: Flow-induced constriction of isolated rat lymph microvessels: Role of constrictor prostanoids. Circulation 96 (1997), 250.
19. 2-liberation from human lymphatics. Lymphology 19 (1986), 79-81.
20. Morrow, ID, U Roberts II: The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol. 51 (1996), 1-9.
21. 2α in human atherosclerotic vascular tissue. Prostagl. Leukotr. and Essent. Fatty Acids 60 (1999), in press.
22. Kritz, H, P Schmid, H Sinzinger: Passive smoking and cardiovascular risk. Arch. Int. Med. 155 (1995), 1942-1948.